Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 1,451–1,460 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1451

    Medicine slug
    talazoparib
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    4
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 1 hour

      Numeric value
      1
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6fd147f-a77e-4a0b-9280-e82ecc41b4be (opens source in a new tab)

        Talazoparib label

        Version not recorded · Effective date not recorded

        Absorption The median time to C max (T max ) was approximately 1 hour (range: 0.4 to 4 hours) after dosing.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b653221e-971f-4452-92d4-797924f1ff59 (opens source in a new tab)

        Talazoparib label

        Version not recorded · Effective date not recorded

        Absorption The median time to C max (T max ) was approximately 1 hour (range: 0.4 to 4 hours) after dosing.

  2. Projected row 1452

    Medicine slug
    talazoparib
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    4
    Source count
    4
    Agreement rate
    1
    Recorded readings

    1. 420 L

      Numeric value
      420
      Unit
      L
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2423edd-6d24-495c-aec1-c2f457f08d9a (opens source in a new tab)

        Talazoparib label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution of talazoparib is 420 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6fd147f-a77e-4a0b-9280-e82ecc41b4be (opens source in a new tab)

        Talazoparib label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution of talazoparib is 420 L.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13839d4f-6acf-4ffb-a128-79df59319273 (opens source in a new tab)

        Talazoparib label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution of talazoparib is 420 L.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b653221e-971f-4452-92d4-797924f1ff59 (opens source in a new tab)

        Talazoparib label

        Version not recorded · Effective date not recorded

        Distribution The mean apparent volume of distribution of talazoparib is 420 L.

  3. Projected row 1453

    Medicine slug
    tamoxifen
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    14
    Source count
    14
    Agreement rate
    1
    Recorded readings

    1. 5 to 7 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      14

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 14 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6c6a643-57d6-7ea5-7da0-e8a66802468a (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:feb96056-79f5-4024-ab0e-fdbb8d4ab862 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:716657e8-d809-4671-87bc-8d10ef69a071 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8c0eb763-420a-4106-ba56-526b53a7f72b (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c82205a3-ae0c-4ce5-b04b-9581cd8c70d4 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b4a8abc-6e56-40c5-a826-1d1f3c0786e1 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e6ff055-590c-41e6-9530-1fdf04cdbd02 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8d731e7e-3b04-49a2-a0f6-3779422174cc (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b8a4211-120f-4981-ad69-928accb97637 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a596c715-8e30-43c1-aba3-4fe5de6729fa (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bb53eeb7-83fc-469e-b9e3-df5f27bfec7b (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5615dbb-3c5e-6ccc-e053-2995a90ab698 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:509f8ba3-214d-aec8-e063-6294a90af498 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days.

  4. Projected row 1454

    Medicine slug
    tamoxifen
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    14
    Source count
    14
    Agreement rate
    1
    Recorded readings

    1. 5 hours

      Numeric value
      5
      Unit
      hours
      Source records
      14

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 14 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6c6a643-57d6-7ea5-7da0-e8a66802468a (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:feb96056-79f5-4024-ab0e-fdbb8d4ab862 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution: Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:716657e8-d809-4671-87bc-8d10ef69a071 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution: Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8c0eb763-420a-4106-ba56-526b53a7f72b (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution: Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c82205a3-ae0c-4ce5-b04b-9581cd8c70d4 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b4a8abc-6e56-40c5-a826-1d1f3c0786e1 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution: Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e6ff055-590c-41e6-9530-1fdf04cdbd02 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption and Distribution Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8d731e7e-3b04-49a2-a0f6-3779422174cc (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution: Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b8a4211-120f-4981-ad69-928accb97637 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution: Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a596c715-8e30-43c1-aba3-4fe5de6729fa (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution: Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bb53eeb7-83fc-469e-b9e3-df5f27bfec7b (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution: Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5615dbb-3c5e-6ccc-e053-2995a90ab698 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution: Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:509f8ba3-214d-aec8-e063-6294a90af498 (opens source in a new tab)

        Tamoxifen label

        Version not recorded · Effective date not recorded

        Absorption and Distribution: Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing.

  5. Projected row 1455

    Medicine slug
    tamsulosin
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    62
    Source count
    62
    Agreement rate
    1
    Recorded readings

    1. 40%

      Numeric value
      40
      Unit
      %
      Source records
      62

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 62 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f543f5d1-3348-4066-99a4-7a00aee1530d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25d5ceab-a04b-4cf0-bc48-3d0c6d8af006 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c963384e-eb50-4462-9aea-ed9d26d267d6 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:db6cb771-2cff-40b7-a5ef-ea3cf2a3b461 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f185abfc-367d-45da-87c4-86d9f70bcd5d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74a8ef78-908f-4671-91a3-ec3a044aabf2 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a2a4cc7-c88a-4555-a247-d1e63206ffc5 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6b6aeab-bedd-4254-8811-4f65cf8a351f (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13a5032d-0be1-4001-916e-459f0b1a051d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00097e78-9c04-4e62-8260-ddb50e9a6a93 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a608ddc8-fe42-484e-b61f-307c60151138 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12ba3063-a134-41e2-8447-45933d4f0f58 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0ad49c7-f57c-45c6-9084-16d8b79c8f87 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d742707b-4c17-4b08-a9d0-491ba2bf6415 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58cba3d8-bb57-4e64-a191-dc050904c896 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9631351f-66f4-45e5-a866-1e59311bd4d7 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3533e74e-5706-f594-e063-6394a90ab8a7 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18e9741b-969a-5a87-e063-6294a90a8851 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8302a6e-b8da-4931-a279-b49e37943816 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a05970e-6c34-4dff-9fd7-dde8ce60f280 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b85769ba-814e-1adb-e053-2a95a90a0556 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:62fa7fdf-c588-6f79-e053-2a91aa0a4c19 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking Tamsulosin Hydrochloride Capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e3206ba-db3e-40b3-b46b-c7ae4703fdea (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d481f6b-0232-d4af-e063-6394a90ad1af (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6142d7b6-e5ea-1af0-e053-2991aa0a00cd (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4202c52-be9d-41d9-b5ff-122740298544 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb120098-b007-4a33-80b8-b7279c7668ee (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions ( Figure 1 ).
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35bbb655-19e2-00c2-e063-6394a90afbe3 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06b44e53-c6e7-4e12-a8fd-572d092cfa70 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking Tamsulosin Hydrochloride Capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7275902e-6832-4e71-997a-d1f7fc1c6a11 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2912fbbc-89bf-4bf0-86fe-bd98f3168e84 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52bbe73b-43b6-3393-e063-6294a90a6dc6 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a420aca-31e6-8e0c-e053-2a91aa0a1be0 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (Cmax) compared to fed conditions (Figure 1). [Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8)] The effec
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9108b999-4b99-469d-99a8-5ef0fa4ca00a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8cb27f78-2d5d-4640-b7b5-ed06973c8133 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:503d080c-9db3-434a-add6-c7d0e5a0ab2e (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59d0e07c-0018-4681-beb2-cb1c8e2637ee (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8de50eca-8cc5-082d-e053-2a95a90a346d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (Cmax) compared to fed conditions (Figure 1). [Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8)] The effec
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9df4fe0-90ab-0d96-e053-2a95a90a5ff1 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3ae55dd-6a0e-4f3a-82b6-2448e0545550 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:199a74b0-47bf-012d-e063-6394a90ac375 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cfd48327-a528-58cc-e053-2995a90a129f (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00bb2d71-1f21-494c-aa66-a82be3a0a8e6 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e9372720-bd02-e4a6-0afd-42fe0c661c00 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87618dfd-eae4-2532-e053-2a95a90a10a0 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6cb939a6-2bc6-5ca0-e053-2991aa0a4e69 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:985871d9-81e2-5fda-e053-2995a90a0338 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14db58df-7584-410b-8cf4-4b928dada859 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:300be29a-c56d-4daa-ba89-f207c281ea20 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36b8c36f-22e5-40f5-a99a-411115f13df4 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8150a710-aee5-4841-ae1b-7d2e61281a8f (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed9988bc-0759-4c36-bee1-11b68dc1c84c (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ed219aa-cf65-457f-8570-d26b48edb240 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd73ddfd-3773-45b2-9795-9e58744a6803 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ab14f88-414a-448f-b7bf-de8c9e1b1eb3 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58bdac81-680a-4fd2-8f05-dd5b86553569 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf583b4a-a99c-4e18-a6d1-8609b5db1a3a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82d65964-de00-42c2-baaa-cc3de744b8eb (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d70b04e-ca08-48d3-937b-eb701b40dd8a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43bec742-fbc4-39af-e063-6294a90ac734 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b30e2bde-b20e-4899-a100-f44170d8165b (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1).

  6. Projected row 1456

    Medicine slug
    tamsulosin
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    62
    Source count
    62
    Agreement rate
    1
    Recorded readings

    1. 5 to 7 hours

      Numeric value
      5
      Unit
      hours
      Source records
      62

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 62 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f543f5d1-3348-4066-99a4-7a00aee1530d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25d5ceab-a04b-4cf0-bc48-3d0c6d8af006 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c963384e-eb50-4462-9aea-ed9d26d267d6 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:db6cb771-2cff-40b7-a5ef-ea3cf2a3b461 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f185abfc-367d-45da-87c4-86d9f70bcd5d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74a8ef78-908f-4671-91a3-ec3a044aabf2 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a2a4cc7-c88a-4555-a247-d1e63206ffc5 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6b6aeab-bedd-4254-8811-4f65cf8a351f (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13a5032d-0be1-4001-916e-459f0b1a051d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00097e78-9c04-4e62-8260-ddb50e9a6a93 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a608ddc8-fe42-484e-b61f-307c60151138 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12ba3063-a134-41e2-8447-45933d4f0f58 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0ad49c7-f57c-45c6-9084-16d8b79c8f87 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d742707b-4c17-4b08-a9d0-491ba2bf6415 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58cba3d8-bb57-4e64-a191-dc050904c896 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9631351f-66f4-45e5-a866-1e59311bd4d7 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3533e74e-5706-f594-e063-6394a90ab8a7 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18e9741b-969a-5a87-e063-6294a90a8851 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8302a6e-b8da-4931-a279-b49e37943816 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a05970e-6c34-4dff-9fd7-dde8ce60f280 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b85769ba-814e-1adb-e053-2a95a90a0556 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:62fa7fdf-c588-6f79-e053-2a91aa0a4c19 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e3206ba-db3e-40b3-b46b-c7ae4703fdea (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d481f6b-0232-d4af-e063-6394a90ad1af (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6142d7b6-e5ea-1af0-e053-2991aa0a00cd (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4202c52-be9d-41d9-b5ff-122740298544 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb120098-b007-4a33-80b8-b7279c7668ee (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35bbb655-19e2-00c2-e063-6394a90afbe3 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06b44e53-c6e7-4e12-a8fd-572d092cfa70 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7275902e-6832-4e71-997a-d1f7fc1c6a11 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2912fbbc-89bf-4bf0-86fe-bd98f3168e84 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52bbe73b-43b6-3393-e063-6294a90a6dc6 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a420aca-31e6-8e0c-e053-2a91aa0a1be0 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9108b999-4b99-469d-99a8-5ef0fa4ca00a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8cb27f78-2d5d-4640-b7b5-ed06973c8133 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:503d080c-9db3-434a-add6-c7d0e5a0ab2e (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59d0e07c-0018-4681-beb2-cb1c8e2637ee (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8de50eca-8cc5-082d-e053-2a95a90a346d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9df4fe0-90ab-0d96-e053-2a95a90a5ff1 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3ae55dd-6a0e-4f3a-82b6-2448e0545550 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:199a74b0-47bf-012d-e063-6394a90ac375 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cfd48327-a528-58cc-e053-2995a90a129f (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00bb2d71-1f21-494c-aa66-a82be3a0a8e6 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e9372720-bd02-e4a6-0afd-42fe0c661c00 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87618dfd-eae4-2532-e053-2a95a90a10a0 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6cb939a6-2bc6-5ca0-e053-2991aa0a4e69 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:985871d9-81e2-5fda-e053-2995a90a0338 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14db58df-7584-410b-8cf4-4b928dada859 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:300be29a-c56d-4daa-ba89-f207c281ea20 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36b8c36f-22e5-40f5-a99a-411115f13df4 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8150a710-aee5-4841-ae1b-7d2e61281a8f (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed9988bc-0759-4c36-bee1-11b68dc1c84c (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ed219aa-cf65-457f-8570-d26b48edb240 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd73ddfd-3773-45b2-9795-9e58744a6803 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ab14f88-414a-448f-b7bf-de8c9e1b1eb3 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58bdac81-680a-4fd2-8f05-dd5b86553569 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf583b4a-a99c-4e18-a6d1-8609b5db1a3a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82d65964-de00-42c2-baaa-cc3de744b8eb (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d70b04e-ca08-48d3-937b-eb701b40dd8a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43bec742-fbc4-39af-e063-6294a90ac734 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b30e2bde-b20e-4899-a100-f44170d8165b (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of tamsulosin hydrochloride in plasma ranged from 5 to 7 hours.

  7. Projected row 1457

    Medicine slug
    tamsulosin
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    62
    Source count
    62
    Agreement rate
    1
    Recorded readings

    1. 94%

      Numeric value
      94
      Unit
      %
      Source records
      62

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 62 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f543f5d1-3348-4066-99a4-7a00aee1530d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25d5ceab-a04b-4cf0-bc48-3d0c6d8af006 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c963384e-eb50-4462-9aea-ed9d26d267d6 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:db6cb771-2cff-40b7-a5ef-ea3cf2a3b461 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f185abfc-367d-45da-87c4-86d9f70bcd5d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74a8ef78-908f-4671-91a3-ec3a044aabf2 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a2a4cc7-c88a-4555-a247-d1e63206ffc5 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6b6aeab-bedd-4254-8811-4f65cf8a351f (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13a5032d-0be1-4001-916e-459f0b1a051d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00097e78-9c04-4e62-8260-ddb50e9a6a93 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a608ddc8-fe42-484e-b61f-307c60151138 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12ba3063-a134-41e2-8447-45933d4f0f58 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0ad49c7-f57c-45c6-9084-16d8b79c8f87 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d742707b-4c17-4b08-a9d0-491ba2bf6415 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58cba3d8-bb57-4e64-a191-dc050904c896 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9631351f-66f4-45e5-a866-1e59311bd4d7 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3533e74e-5706-f594-e063-6394a90ab8a7 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18e9741b-969a-5a87-e063-6294a90a8851 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8302a6e-b8da-4931-a279-b49e37943816 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a05970e-6c34-4dff-9fd7-dde8ce60f280 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b85769ba-814e-1adb-e053-2a95a90a0556 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:62fa7fdf-c588-6f79-e053-2a91aa0a4c19 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e3206ba-db3e-40b3-b46b-c7ae4703fdea (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d481f6b-0232-d4af-e063-6394a90ad1af (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6142d7b6-e5ea-1af0-e053-2991aa0a00cd (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4202c52-be9d-41d9-b5ff-122740298544 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb120098-b007-4a33-80b8-b7279c7668ee (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35bbb655-19e2-00c2-e063-6394a90afbe3 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06b44e53-c6e7-4e12-a8fd-572d092cfa70 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7275902e-6832-4e71-997a-d1f7fc1c6a11 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2912fbbc-89bf-4bf0-86fe-bd98f3168e84 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52bbe73b-43b6-3393-e063-6294a90a6dc6 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a420aca-31e6-8e0c-e053-2a91aa0a1be0 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9108b999-4b99-469d-99a8-5ef0fa4ca00a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8cb27f78-2d5d-4640-b7b5-ed06973c8133 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:503d080c-9db3-434a-add6-c7d0e5a0ab2e (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59d0e07c-0018-4681-beb2-cb1c8e2637ee (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8de50eca-8cc5-082d-e053-2a95a90a346d (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9df4fe0-90ab-0d96-e053-2a95a90a5ff1 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3ae55dd-6a0e-4f3a-82b6-2448e0545550 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:199a74b0-47bf-012d-e063-6394a90ac375 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cfd48327-a528-58cc-e053-2995a90a129f (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00bb2d71-1f21-494c-aa66-a82be3a0a8e6 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e9372720-bd02-e4a6-0afd-42fe0c661c00 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87618dfd-eae4-2532-e053-2a95a90a10a0 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6cb939a6-2bc6-5ca0-e053-2991aa0a4e69 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:985871d9-81e2-5fda-e053-2995a90a0338 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14db58df-7584-410b-8cf4-4b928dada859 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:300be29a-c56d-4daa-ba89-f207c281ea20 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36b8c36f-22e5-40f5-a99a-411115f13df4 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8150a710-aee5-4841-ae1b-7d2e61281a8f (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed9988bc-0759-4c36-bee1-11b68dc1c84c (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a242c8dc-576e-4a1f-a9e7-a05d7ebc0e0a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ed219aa-cf65-457f-8570-d26b48edb240 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd73ddfd-3773-45b2-9795-9e58744a6803 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ab14f88-414a-448f-b7bf-de8c9e1b1eb3 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58bdac81-680a-4fd2-8f05-dd5b86553569 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf583b4a-a99c-4e18-a6d1-8609b5db1a3a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82d65964-de00-42c2-baaa-cc3de744b8eb (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d70b04e-ca08-48d3-937b-eb701b40dd8a (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43bec742-fbc4-39af-e063-6294a90ac734 (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b30e2bde-b20e-4899-a100-f44170d8165b (opens source in a new tab)

        Tamsulosin label

        Version not recorded · Effective date not recorded

        Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha 1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL).

  8. Projected row 1458

    Medicine slug
    tapentadol
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    6
    Source count
    6
    Agreement rate
    0.666667
    Recorded readings

    1. 4 hours

      Numeric value
      4
      Unit
      hours
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80938c30-9fe3-4c7d-9d9c-5476638cfb2d (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The terminal half-life is on average 4 hours after oral administration.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fecd2104-5bf3-47ed-a6f0-5c6ebb0a17b4 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The terminal half-life is on average 4 hours after oral administration.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0ecb809-6a55-4afe-b981-b8f174e5c344 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The terminal half-life is on average 4 hours after oral administration.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:863f3fd3-1e8d-41b0-855f-8f9a29237cda (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The terminal half-life is on average 4 hours after oral administration.

    2. 5 hours

      Numeric value
      5
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38de863e-56ff-4c43-9ab8-9b3e1ba82858 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The terminal half-life is on average 5 hours after oral administration.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3d04d70-0155-4147-9ce4-a3b1fad4b373 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The terminal half-life is on average 5 hours after oral administration.

  9. Projected row 1459

    Medicine slug
    tapentadol
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    6
    Agreement rate
    1
    Recorded readings

    1. 20%

      Numeric value
      20
      Unit
      %
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80938c30-9fe3-4c7d-9d9c-5476638cfb2d (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The plasma protein binding is low and amounts to approximately 20%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fecd2104-5bf3-47ed-a6f0-5c6ebb0a17b4 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The plasma protein binding is low and amounts to approximately 20%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38de863e-56ff-4c43-9ab8-9b3e1ba82858 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The plasma protein binding is low and amounts to approximately 20%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0ecb809-6a55-4afe-b981-b8f174e5c344 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The plasma protein binding is low and amounts to approximately 20%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:863f3fd3-1e8d-41b0-855f-8f9a29237cda (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The plasma protein binding is low and amounts to approximately 20%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3d04d70-0155-4147-9ce4-a3b1fad4b373 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        The plasma protein binding is low and amounts to approximately 20%.

  10. Projected row 1460

    Medicine slug
    tapentadol
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    6
    Agreement rate
    1
    Recorded readings

    1. 540 +/- 98 L

      Numeric value
      540
      Unit
      L
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80938c30-9fe3-4c7d-9d9c-5476638cfb2d (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        Following intravenous administration, the volume of distribution (Vz) for tapentadol is 540 +/- 98 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fecd2104-5bf3-47ed-a6f0-5c6ebb0a17b4 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        Following intravenous administration, the volume of distribution (V z ) for tapentadol is 540 +/- 98 L.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38de863e-56ff-4c43-9ab8-9b3e1ba82858 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        Following intravenous administration, the volume of distribution (Vz) for tapentadol is 540 +/- 98 L.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0ecb809-6a55-4afe-b981-b8f174e5c344 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        Following intravenous administration, the volume of distribution (Vz) for tapentadol is 540 +/-98 L.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:863f3fd3-1e8d-41b0-855f-8f9a29237cda (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        Following intravenous administration, the volume of distribution (Vz) for tapentadol is 540 +/- 98 L.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3d04d70-0155-4147-9ce4-a3b1fad4b373 (opens source in a new tab)

        Tapentadol label

        Version not recorded · Effective date not recorded

        Following intravenous administration, the volume of distribution (Vz) for tapentadol is 540 +/- 98 L.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=1450

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy